Chardan Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $23
Buy Rating for Lexeo Therapeutics Backed by Strong Finances and Promising Clinical Trials
Lexeo Therapeutics Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
Lexeo Therapeutics Analyst Ratings
Baird Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $28
Leerink Partners Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $20
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
RBC Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $24
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy From RBC Capital
Buy Rating Affirmed for Lexeo Therapeutics Amid Anticipated Catalysts and Solid Financials
H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $21
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $21
Stifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Analysts Are Bullish on These Healthcare Stocks: Instil Bio (TIL), Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target
Buy Rating Affirmed for Lexeo Therapeutics Amid Promising Clinical Trial Results for FA-CM Treatment
Analysts Offer Insights on Healthcare Companies: InMode (INMD), Fortrea Holdings Inc. (FTRE) and Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics Analyst Ratings
No Data
No Data